A daily dose of clinical news on Patient Care you may have missed.
Advertisement
Patient Care brings primary care clinicians a lot of medical news every day—it’s easy to miss an important study. The Daily Dose provides a concise summary of one of the website's leading stories you may not have seen.
On July 25, 2023, we reported on a study published in the Journal of the American Heart Association that aimed to develop and validate predictive models using early pregnancy blood pressure (BP) trajectory patterns in the first 20 weeks of pregnancy for improved risk stratification for early‐ and later‐onset preeclampsia, and gestational hypertension (HTN).
The study
Researchers analyzed BP measurements and other data from the electronic medical records of approximately 250 000 healthy pregnant patients who gave birth at Kaiser Permanente Northern California hospitals between 2009 and 2019, all of whom were considered to be at low-to-moderate risk of developing hypertensive disorders of pregnancy based on US Preventive Services Task Force criteria. Patients with high-risk conditions, such as prior chronic hypertension, liver disease, or kidney disease, were excluded from the study.
The findings
From that data, the researchers developed and validated the 6 trajectories, which elicited “excellent” discrimination, with C-statistics ranging from 0.731 to 0.770. The observed discrimination, explained the researchers, was superior to that observed when using risk factors alone (0.688-0.695).
Three of the 6 BP trajectories observed in the first 20 weeks of pregnancy were able to identify nearly 3 in 4 patients (74%) who subsequently developed preeclampsia in the latter half of their pregnancy as well as 82% of gestational hypertension outcomes in more than half (52%) of the study group.
Authors' commentary
"In the future, these findings may be translated into an automated clinical tool within the electronic health records system, or a web‐based tool to classify BP pattern changes during early gestation for individual risk stratification of preeclampsia or gestational hypertension that may improve precision medicine by more accurately identifying patients who may truly benefit most from enhanced monitoring and intervention(s)."
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
TMS 2026: OB/GYN visits had nearly 4-fold higher odds of menopause coding than family medicine visits, with disparities by race and insurance, a study found.
TMS 2026: Menopause hormone therapy was associated with greater weight loss on semaglutide, but not sustained additional benefits with tirzepatide, in a new study.
TMS 2026: A meta-analysis of 5 studies found hormone therapy linked to more frequent migraine attacks and migraine days, but not greater severity or analgesic use.
TMS 2026: Post hoc OASIS 1 and 2 data show more women on elinzanetant reported improvement across all 8 PROMIS sleep disturbance items vs placebo at week 12.